GlassScriptPhysician profile
Robert A Mcknight
NPI 1407870462
$2,999.35
in general payments reported to CMS, 2019-2025
29 companies · $28.34 in 2025
The $28.34 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $42.17 · 2021: $723 · 2022: $1,367 · 2023: $696 · 2024: $19.01 · 2025: $28.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,095.68 | 2021-2023 | |
| Lilly USA, LLC | $301.50 | 2021-2023 | Taltz, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $193.83 | 2019-2023 | Xifaxan |
| Novo Nordisk INC | $180.86 | 2021-2023 | Rybelsus, Ozempic |
| Radius Health, INC. | $162.59 | 2023-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $133.49 | 2021-2023 | |
| Amarin Pharma, INC. | $129.21 | 2020-2023 | |
| Glaxosmithkline, LLC. | $127.47 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $80.68 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $74.89 | 2019-2022 | |
| Pfizer INC. | $67.16 | 2019-2021 | |
| Abbott Laboratories | $66.07 | 2021 | |
| Merck Sharp & Dohme LLC | $52.56 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $44.17 | 2019-2022 | |
| Allergan, INC. | $43.36 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $30.76 | 2021 | |
| Amneal Pharmaceuticals LLC | $25.09 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.80 | 2022 | |
| Lundbeck LLC | $21.64 | 2022 | |
| Axsome Therapeutics, INC. | $19.68 | 2023 | Auvelity |
| Tris Pharma INC | $15.95 | 2023 | Dyanavel Xr |
| Corcept Therapeutics | $15.34 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.06 | 2019 | |
| Averitas Pharma INC. | $14.59 | 2023 | Qutenza |
| Sumitomo Pharma America, INC. | $14.19 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $13.38 | 2022 | |
| Currax Pharmaceuticals LLC | $12.61 | 2022 | |
| Ibsa Pharma INC. | $12.38 | 2022 | |
| Amgen INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcknight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.